Shan Y - Search Results

1

Discovery of novel VEGFR-2 inhibitors. Part 5: Exploration of diverse hinge-binding fragments via core-refining approach.

Shan Y, Gao H, Shao X, Wang J, Pan X, Zhang J. Shan Y, et al. Eur J Med Chem. 2015 Oct 20;103:80-90. doi: 10.1016/j.ejmech.2015.08.045. Epub 2015 Aug 29. Eur J Med Chem. 2015. PMID: 26342134

2

Synthesis and preliminary biological evaluation of novel taspine derivatives as anticancer agents.

Zhang J, Zhang Y, Shan Y, Li N, Ma W, He L. Zhang J, et al. Among authors: shan y. Eur J Med Chem. 2010 Jul;45(7):2798-805. doi: 10.1016/j.ejmech.2010.03.001. Epub 2010 Mar 7. Eur J Med Chem. 2010. PMID: 20304537

3

Molecular docking, 3D-QSAR studies, and in silico ADME prediction of p-aminosalicylic acid derivatives as neuraminidase inhibitors.

Zhang J, Shan Y, Pan X, Wang C, Xu W, He L. Zhang J, et al. Among authors: shan y. Chem Biol Drug Des. 2011 Oct;78(4):709-17. doi: 10.1111/j.1747-0285.2011.01179.x. Epub 2011 Sep 6. Chem Biol Drug Des. 2011. PMID: 21752201

4

Development of 5-Fluorouracil derivatives as anticancer agents.

Pan X, Wang C, Wang F, Li P, Hu Z, Shan Y, Zhang J. Pan X, et al. Among authors: shan y. Curr Med Chem. 2011;18(29):4538-56. doi: 10.2174/092986711797287584. Curr Med Chem. 2011. PMID: 21864282 Review.

5

Recent advances in the structure-based design of neuraminidase inhibitors as antiinfluenza agents.

Shan Y, Ma Y, Wang M, Dong Y. Shan Y, et al. Curr Med Chem. 2012;19(34):5885-94. doi: 10.2174/092986712804143358. Curr Med Chem. 2012. PMID: 22963668 Review.

6

Recent progress in the development of histone deacetylase inhibitors as anti-cancer agents.

Zhang L, Lei J, Shan Y, Yang H, Song M, Ma Y. Zhang L, et al. Among authors: shan y. Mini Rev Med Chem. 2013 Dec;13(14):1999-2013. doi: 10.2174/13895575113136660102. Mini Rev Med Chem. 2013. PMID: 24160707 Review.

7

Discovery of biphenyl-based VEGFR-2 inhibitors. Part 3: design, synthesis and 3D-QSAR studies.

Lu W, Li P, Shan Y, Su P, Wang J, Shi Y, Zhang J. Lu W, et al. Among authors: shan y. Bioorg Med Chem. 2015 Mar 1;23(5):1044-54. doi: 10.1016/j.bmc.2015.01.006. Epub 2015 Jan 9. Bioorg Med Chem. 2015. PMID: 25637123

8

Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine.

Shan Y, Dong J, Pan X, Zhang L, Zhang J, Dong Y, Wang M. Shan Y, et al. Eur J Med Chem. 2015 Nov 2;104:139-47. doi: 10.1016/j.ejmech.2015.09.034. Epub 2015 Oct 8. Eur J Med Chem. 2015. PMID: 26451772

9

Expanding the structural diversity of diarylureas as multi-target tyrosine kinase inhibitors.

Shan Y, Wang C, Zhang L, Wang J, Wang M, Dong Y. Shan Y, et al. Bioorg Med Chem. 2016 Feb 15;24(4):750-8. doi: 10.1016/j.bmc.2015.12.038. Epub 2015 Dec 23. Bioorg Med Chem. 2016. PMID: 26753815

10

Discovery of novel anti-angiogenesis agents. Part 6: Multi-targeted RTK inhibitors.

Zhang L, Shan Y, Li C, Sun Y, Su P, Wang J, Li L, Pan X, Zhang J. Zhang L, et al. Among authors: shan y. Eur J Med Chem. 2017 Feb 15;127:275-285. doi: 10.1016/j.ejmech.2016.12.059. Epub 2017 Jan 2. Eur J Med Chem. 2017. PMID: 28068599

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,673 results

Search Page

Filters